Regulation of platelet-activating factor (PAF) activity in human diseases by phospholipase A2 inhibitors, PAF acetylhydrolases, PAF receptor antagonists and free radical scavengers

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 61, Issue 2, 1999, Pages 65-82

  Peplow, P V ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; 3,5 DIMETHYL 2 (3 PYRIDYL) 4 THIAZOLIDINONE; 7 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY) 2 HYDROXYPROPOXY] 4 OXO 8 PROPYL 4H 1 BENZOPYRAN 2 CARBOXYLIC ACID; ALPHA TOCOPHEROL; ANTIOXIDANT; APAFANT; BEPAFANT; CD11B ANTIGEN; CELL ADHESION MOLECULE; CLORICROMEN; CYTOKINE; FOROPAFANT; GINKGOLIDE B; INTERCELLULAR ADHESION MOLECULE 1; L SELECTIN; LEXIPAFANT; LIPID; LOW DENSITY LIPOPROTEIN; NIMESULIDE; OXYGEN RADICAL; PADGEM PROTEIN; PHOSPHOLIPASE A2 INHIBITOR; RO 24 4736; SCAVENGER; SR 27388; SUPEROXIDE DISMUTASE; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; UNCLASSIFIED DRUG; [2 METHOXY 3 (N OCTADECYLCARBAMOYLOXY)PROPYL] (2 THIAZOLIOETHYL) PHOSPHATE;

ACUTE PANCREATITIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ASTHMA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL ACTIVATION; CELL ADHESION; CELL DEATH; CELL INTERACTION; CELL MEMBRANE; CELL MIGRATION; COLITIS; CYTOKINE RELEASE; CYTOTOXICITY; DIABETES MELLITUS; ENDOTHELIUM CELL; ENZYME RELEASE; GASTROINTESTINAL DISEASE; HUMAN; INFLAMMATORY DISEASE; KIDNEY ISCHEMIA; LEUKOCYTE; LIPID OXIDATION; LUNG INJURY; MEDIATOR; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; SEPSIS; TISSUE INJURY;

EID: 0032829605     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1054/plef.1999.0038     Document Type: Article

References (138)

1. Bessin P., Bonnet J., Apffel D. Acute circulatory collapse caused by platelet activating factor (PAF-acether) in dogs. Eur J Phmacol. 86:1983;403-413.
2. Levi R., Burke J. A., Guo Z. G. Acetyl glyceryl ether phosphorylcholine (AGEPC). A putative mediator of cardiac anaphylaxis in the guinea pig. Circ Res. 54:1984;117-124.
3. Snyder F. Chemical and biochemical aspects of platelet activating factor: a novel class of acetylated ether-linked choline-phospholipids. Med Res Rev. 5:1985;107-140.
4. Lepran I., Lefer A. M. Ischemia aggravating effects of platelet-activating factor in acute myocardial ischemia. Basic Res Cardiol. 80:1985;135-141.
5. Chilton F. H., Ellis J. M., Olson S. C., Wykle R. L. 1-O-Alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine. A common source of platelet-activating factor and arachidonate in human polymorphonuclear leukocytes. J Biol Chem. 259:1984;12014-12019.
6. Kramer R. M., Jakubowski J. A., Deykin D. Hydrolysis of 1-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine, a common precursor of platelet-activating factor and eicosanoids, by human platelet phospholipase A2. Biochim Biophys Acta. 959:1988;269-279.
7. Peplow P. V., Mikhailidis D. P. Platelet-activating factor (PAF) and its relation to prostaglandins, leukotrienes and other aspects of arachidonate metabolism. Prostaglandins Leukot Essent Fatty Acids. 41:1990;71-82.
8. Zimmerman G. A., Prescott S. M., McIntyre T. M. Platelet-activating factor: a fluid phase and a cell-associated mediator of inflammation. Gallen J. L., Goldstein I. M., Snyderman R. Inflammation: Basic Principles and Clinical Correlates, 2nd edn. 1992;149-176 Raven Press, New York.
9. Zimmerman G. A., Lorant D. E., McIntyre T. M., Prescott S. M. Juxtacrine intercellular signalling: another way to do it. Am J Resp Cell Mol Biol. 9:1993;573-577.
10. Francescangeli E., Domanska-Janik K., Goracci G. Relative contribution of the de novo and remodelling pathways to the synthesis of platelet-activating factor in brain areas and during ischemia. J Lipid Mediators Cell Signalling. 14:1996;89-98.
11. Hattori M., Aoki J., Arai H., Inoue K. PAF and PAF acetylhydrolase in the nervous system. J Lipid Mediators Cell Signalling. 14:1996;99-102.
12. Ho Y. S., Swenson L., Derewenda U. Brain acetylhydrolase that inactivates platelet-activating factor is a G-protein-like trimer. Nature. 385:1997;89-93.
13. Tselepsis A. D., Dentan C., Karabina S. A., Chapman M. J., Ninio E. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arteriosclerosis Thromb Vasc Biol. 15:1995;1764-1773.
14. 2plus;-induced oxidative modification in vitro. Atherosclerosis. 125:1996;121-134.
15. Blencowe C., Hermetter A., Kostner G. M., Deigner H. P. Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein (a) in comparison with low density lipoprotein. J Biol Chem. 270:1995;31151-31157.
16. Stafforini D. M., Elstad M. R., McIntyre T. M. Human macrophages secrete platelet-activating factor acetylhydrolase. J Biol Chem. 265:1990;9682-9687.
17. Tarbet E. B., Stafforini D. M., Elstad M. R. Liver cells secrete the plasma form of platelet-activating factor acetylhydrolase. J Biol Chem. 266:1991;16667-16673.
18. Elstad M. R., Stafforini D. M., McIntyre T. M., Prescott S. M., Zimmerman G. A. Platelet-activating factor acetylhydrolase increases during macrophage differentiation. A novel mechanism that regulates accumulation of platelet-activating factor. J Biol Chem. 264:1989;8467-8470.
19. Stremler K. E., Stafforini D. M., Prescott S. M., McIntyre T. M. Human plasma platelet-activating factor acetylhydrolase. Oxidatively fragmented phospholipids as substrates. J Biol Chem. 266:1991;11095-11103.
20. Miwa M., Miyake T., Yamanaka T. Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J Clin Invest. 82:1988;1983-1991.
21. Miyaura S., Maki N., Byrd W., Johnston J. M. The hormonal regulation of platelet-activating factor acetylhydrolase activity in plasma. Lipids. 26:1991;1015-1020.
22. Narahara H., Johnston J. M. Effects of endotoxins and cytokines on the secretion of platelet-activating factor-acetylhydrolase by human decidual macrophages. Am J Obstet Gynecol. 169:1993;531-537.
23. Satoh K., Imaizumi T., Kawamura Y. Platelet-activating factor (PAF) stimulates the production of PAF acetylhydrolase by the human hepatoma cell line, HepG2. J Clin Invest. 87:1991;476-481.
24. Patel K. D., Lorant E., Jones D. A. Juxtacrine interactions of endothelial cells with leukocytes: tethering and signaling molecules. Behring Institute Mitteilungen. 92:1993;144-116.
25. Lorant D. E., McEver R. P., McIntyre T. M. Activation of polymorphonuclear leukocytes reduces their adhesion to P-selectin and causes redistribution of ligands for P-selectin on their surfaces. J Clin Invest. 96:1995;171-182.
26. Lorant D. E., Zimmerman G. A., McIntyre T. M., Prescott S. M. Platelet-activating factor mediates procoagulant activity on the surface of endothelial cells by promoting leukocyte adhesion. Seminars in Cell Biol. 6:1995;295-303.
27. Zimmerman G. A., Elstad M. R., Lorant D. E. Platelet-activating factor (PAF): signalling and adhesion in cell-cell interactions. Adv Exptl Med Biol. 416:1996;297-304.
28. Muller E., Dagenais P., Alami N., Rola-Pleszczynski M. Identification and functional characterization of platelet-activating factor receptors in human leukocyte populations using polyclonal anti-peptide antibody. Proc Natl Acad Sci USA. 90:1993;5818-5822.
29. Rola-Pleszczynski M., Thivierge M., Ouellet S. Cytokines and eicosanoids regulate PAF receptor gene expression. Adv Prost Thromb Leuk Res. 23:1995;287-292.
30. Ouellet S., Muller E., Rola-Pleszczynski M. IFN-γ up-regulates platelet-activating factor receptor gene expression in human monocytes. J Immunol. 152:1994;5092-5099.
31. Thivierge M., Alami N., Muller E., de Brum-Fernandes A. J., Rola-Pleszczynski M. Transcriptional modulation of platelet-activating factor receptor gene expression by cyclic AMP. J Biol Chem. 268:1993;17457-17462.
32. Thivierge M., Parent J. L., Stankova J., Rola-Pleszczynski M. Modulation of human platelet-activating factor receptor gene expression by protein kinase C activation. J Immunol. 157:1996;4681-4687.
33. Kishimoto S., Shimazu W., Izumi T. Enhanced expression of platelet-activating factor receptor on human eosinophils by interleukin-3, interleukin-5 and granulocyte-macrophage colony-stimulating factor. Int Arch Allergy Immunol. 111:1996;63-65.
34. Zimmerman G. A., McIntyre T. M., Mehra M., Prescott S. M. Endothelial cell-associated platelet-activating factor: a novel mechanism for signaling intercellular adhesion. J Cell Biol. 110:1990;529-540.
35. Neeley S. P., Hamann K. J., White S. R. Selective regulation of expression of surface adhesion molecules Mac-1, L-selectin, and VLA-4 on human eosinophils and neutrophils. Am J Resp Cell Mol Biol. 8:1993;633-639.
36. Berends C., Dijkhuizen B., de Monchy J. G. Inhibition of PAF-induced expression of CD11β and shedding of L-selectin on human neutrophils and eosinophils by the type IV selective PDE inhibitor, rolipram. Eur Resp J. 10:1997;1000-1007.
37. Horie S., Kita H. CD11β/CD18 (Mac-1) is required for degranulation of human eosinophils induced by human recombinant granulocyte-macrophage colony-stimulating factor and platelet-activating factor. J Immunol. 152:1994;5457-5467.
38. Simon S. I., Burns A. R., Taylor A. D. L-selectin (CD62L) cross-linking signals neutrophil adhesive functions via the Mac-1 (CD11β/CD18) beta 2-integrin. J Immunol. 155:1995;1502-1514.
39. Fattah D., Page K. R., Bezbaruah S. A rapid activation assay for human eosinophils based on adhesion to immobilized ICAM-1, VCAM-1 and IgG. Cytokine. 8:1996;248-259.
40. Elstad M. R., La Pine T. R., Cowley F. S. P-selectin regulates platelet-activating factor synthesis and phagocytosis by monocytes. J Immunol. 155:1995;2109-2122.
41. Schmid E., Muller T. H., Budzinski R. M., Pfizenmaier K., Binder K. Lymphocyte adhesion to human endothelial cells induces tissue factor expression via a juxtacrine pathway. Thromb Haemostasis. 73:1995;421-428.
42. Bruehl R. E., Moore K. L., Lorant D. E. Leukocyte activation induces surface redistribution of P-selectin glycoprotein ligand-1. J Leukocyte Biol. 61:1997;489-499.
43. Weyrich A. S., McIntyre T. M., McEver R. P., Prescott S. M., Zimmerman G. A. Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-alpha secretion. Signal integration and NF-kappa B translocation. J Clin Invest. 95:1995;2297-2303.
44. Burton J. L., Kehrli M. E., Kapil S., Horst R. L. Regulation of L-selectin and CD18 on bovine neutrophils by glucocorticoids: effects of cortisol and dexamethasone. J Leukocyte Biol. 57:1995;317-325.
45. Schwartz J. D., Shamamian P., Grossi E. A. Lexipafant inhibits platelet-activating factor enhanced neutrophil functions. J Surg Res. 69:1997;240-248.
46. Poch B., Gansauge F., Gansauge S. Release of histamine in whole blood by oxygen radicals: division between specific and unspecific processes. Inflamm Res. 45:1996;428-433.
47. Ambrosio G., Oriente A., Napoli C. Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet-activating factor. J Clin Invest. 93:1994;2408-2416.
48. 2and their functions. Compt Rend Seances Soc Biol Ses Filiales. 190:1996;409-416.
49. 2enzymes: selective inhibitors and their pharmacological potential. Adv Pharmacol. 32:1995;31-66.
50. Franciose R. J., Moore E. E., Moore F. A. Hypoxia/reoxygenation of human endothelium activates PMNs to detach endothelial cells via a PAF mechanism. J Surg Res. 61:1996;459-462.
51. Westlin W. F., Gimbrone M. A. Neutrophil-mediated damage to human vascular endothelium. Role of cytokine activation. Am J Pathol. 142:1993;117-128.
52. Hsueh W., Gonzalez-Crussi F., Arroyave J. L. Release of leukotriene C4 by isolated, perfused rat small intestine in response to platelet-activating factor. J Clin Invest. 78:1986;108-114.
53. Tan X. D., Wang H., Gonzalez-Crussi F. X. Platelet-activating factor and endotoxin increase the enzyme activity and gene expression of type II phospholipase A2 in the rat intestine. Role of polymorphonuclear leukocytes. J Immunol. 156:1996;2985-2990.
54. Tool A. T., Verhoeven A. J. Inhibition of the production of platelet activating factor and of leukotriene B4 in activated neutrophils by nimesulide due to an elevation of intracellular cyclic adenosine monophosphate. Arzneimittel-Forschung. 45:1995;1110-1114.
55. Ribaldi E., Mezzasoma A. M., Francescangeli E. Inhibition of PAF synthesis by stimulated human polymorphonuclear leucocytes with cloricromene, an inhibitor of phospholipase A2 activation. Br J Pharm. 118:1996;1351-1358.
56. Blank M. L., Snyder F., Byers L. W., Brooks B., Muirhead E. E. Antihypertensive activity of an alkyl ether analog of phosphatidylcholine. Biochem Biophys Res Commn. 90:1979;1194-1200.
57. Masugi F., Ogihara T., Otsuka A., Saeki S., Kumahara Y. Potent hypotensive activity of 1-O-hexadecyl-2-O-acetyl-SN-glycero-3-phosphocholine in spontaneously hypertensive rat. Biochem Biophys Res Commn. 104:1982;280-284.
58. Masugi F., Ogihara T., Otsuka A., Saeki S., Kumahara Y. Effect of 1-alkyl-2-acetyl-sn-glycero-3-phosphorylcholine inhibitor on the reduction of one-kidney, one clip hypertension after unclipping in the rat. Life Sci. 34:1984;197-201.
59. Dzau V. J., Gibbons G. H., Morishita R., Pratt R. E. New perspectives in hypertension research. Potentials of vascular biology. Hypertension. 23:1994;1132-1140.
60. Satoh K., Imaizumi T. A., Kawamura Y. Increased activity of the platelet-activating factor acetylhydrolase in plasma low density lipoprotein from patients with essential hypertension. Prostaglandins. 37:1989;673-682.
61. Saeki S., Masugi F., Ogihara T. Effects of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet activating factor) on cardiac function in perfused guinea-pig heart. Life Sci. 37:1985;325-329.
62. Stahl G. L., Lefer D. J., Lefer A. M. PAF-acether induced cardiac dysfunction in the isolated perfused guinea pig heart. Naunyn-Schmiedebergs Arch Pharmacol. 336:1987;459-463.
63. Stahl G. L., Lefer A. M. Mechanisms of platelet-activating factor-induced cardiac depression in the isolated perfused rat heart. Circ Shock. 23:1987;165-177.
64. Wainwright C. L., Parratt J. R., Bigaud M. The effects of PAF antagonists on arrhythmias and platelets during acute myocardial ischaemia and reperfusion. Eur Heart J. 10:1989;235-243.
65. Ostermann G., Ruhling K., Zabel-Langhennig R. Plasma from atherosclerotic patients exerts an increased degradation of platelet-activating factor. Thromb Res. 47:1987;279-285.
66. Ostermann G., Lang A., Holtz H. The degradation of platelet-activating factor in serum and its discriminative value in atherosclerotic patients. Thromb Res. 52:1988;529-540.
67. Graham R. M., Stephens C. J., Sturm M. J., Taylor R. R. Plasma platelet-activating factor degradation in patients with severe coronary artery disease. Clin Sci. 82:1992;535-541.
68. Yamada Y., Yokota M. Loss of activity of plasma platelet-activating factor acetylhydrolase due to a novel Gln281- →Arg mutation. Biochem Biophys Res Commn. 236:1997;772-775.
69. Yamada Y., Ichihara S., Fujimura T., Yokota M. Identification of the G994- →T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metab Clin Exptl. 47:1998;177-181.
70. Yoshida H., Satoh K., Takamatsu S. Platelet-activating factor acetylhydrolase in red cell membranes. Does decreased activity impair erythrocyte deformability in ischemic stroke patients. Stroke. 24:1993;14-18.
71. Ernst E., Matrai A., Marshall M. Blood rheology in patients with transient ischemic attacks. Stroke. 19:1988;634-636.
72. Fisher M., Meiselman H. J. Hemorheological factors in cerebral ischemia. Stroke. 22:1991;1164-1169.
73. Gaylord M. S., Smith Z. L., Lorch V., Blank M. L., Snyder F. Altered platelet-activating factor levels and acetylhydrolase activities are associated with increasing severity of bronchopulmonary dysplasia. Am J Med Sci. 312:1996;149-154.
74. Tsukioka K., Matsuzaki M., Nakamata M., Kayahara H., Nakagawa T. Increased plasma level of platelet-activating factor (PAF) and decreased serum PAF acetylhydrolase (PAFAH) activity in adults with bronchial asthma. J Invest Allergology Clin Immunol. 6:1996;22-29.
75. Triggiani M., De Marino V., Sofia M. Characterization of platelet-activating factor acetylhydrolase in human bronchoalveolar lavage. Am J Resp Crit Care Med. 156:1997;94-100.
76. Kald B., Smedh K., Olaison G., Sjodahl R., Tagesson C. Platelet-activating factor acetylhydrolase activity in intestinal mucosa and plasma of patients with Crohn,'s disease. Digestion. 57:1996;472-477.
77. Guimbaud R., Izzo A., Martinolle J. P. Intraluminal excretion of PAF, lysoPAF, and acetylhydrolase in patients with ulcerative colitis. Digestive Diseases Sci. 40:1995;2635-2640.
78. Furukawa M., Lee E. L., Johnston J. M. Platelet-activating factor-induced ischemic bowel necrosis: the effect of platelet-activating factor acetylhydrolase. Pediatric Res. 34:1993;237-241.
79. Meade C. J., Birke F., Metcalfe S. Serum PAF-acetylhydrolase in severe renal or hepatic disease in man: relationship to circulating levels of PAF and effects of nephrectomy or transplantation. J Lipid Med Cell Signalling. 9:1994;205-215.
80. Iatrou C., Moustakas G., Antonopoulou S., Demopoulos C. A., Ziroyiannis P. Platelet-activating factor levels and PAF acetylhydrolase activities in patients with primary glomerulonephritis. Nephron. 72:1996;611-616.
81. Lindner A., Charra B., Sherrard D. L., Scribner B. H. Accelerated atherosclerosais in prolonged maintenance hemodialysis. N Eng J Med. 290:1974;697-701.
82. Raine A. E., Margreiter R., Brunner F. P. Report on management of renal failure in Europe, XXII, 1991. Nephrol Dialysis Transplant. 7:1992;7-35.
83. Maggi E., Bellazzi R., Falaschi F. Enhanced LDL oxidation in uremic patients: an additional mechanism for accelerated atherosclerosis. Kidney Int. 45:1994;876-883.
84. Panzetta O., Cominacini L., Garbin U. Increased susceptibility of LDL to in vitro oxidation in patients on maintenance hemodialysis: effects of fish oil and vitamin E administration. Clin Nephrol. 44:1995;303-309.
85. Loughrey C. M., Young I. S., McEneny J. Oxidation of low density lipoprotein in patients on regular hemodialysis. Atherosclerosis. 110:1994;185-193.
86. Westhuyzen J., Saltissi D., Healy H. Oxidation of low density lipoprotein in hemodialysis patients: effect of dialysis and comparison with matched controls. Atherosclerosis. 129:1997;199-205.
87. Hasselwander O., McMaster D., Fogarty D. G. Serum paraoxonase and platelet-activating factor acetylhydolase in chronic renal failure. Clin Chem. 44:1998;179-181.
88. Witztum J. L., Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 88:1991;1785-1792.
89. Hofmann B., Ruhling K., Spangenberg P., Ostermann G. Enhanced degradation of platelet-activating factor in serum from diabetic patients. Haemostasis. 19:1989;180-184.
90. Nathan N., Denizot Y., Huc M. C. Elevated levels of paf-acether in blood of patients with type 1 diabetes mellitus. Diabete Metabolisme. 18:1992;59-62.
91. Greco N. J., Arnold J. H., O'Dorisio T. M., Cataland S., Panganamala R. V. Action of platelet-activating factor on type 1 diabetic human platelets. J Lab Clin Med. 105:1985;410-416.
92. Maki N., Magness R. R., Miyaura S., Gant N. F., Johnston J. M. Platelet-activating factor-acetylhydrolase activity in normotensive and hypertensive pregnancies. Am J Obstet Gynecol. 168:1993;50-45.
93. Kobayashi F., Sagawa N., Ihara Y. Platelet-activating factor-acetylhydolase activity in maternal and umbilical venous plasma obtained from normotensive and hypertensive pregnancies. Obstet Gynecol. 84:1994;360-364.
94. Tetta C., Bussolino F., Modena V. Release of platelet-activating factor in systemic lupus erythematosus. Internat Arch Allergy Appl Immunol. 91:1990;244-256.
95. Hilliquin P., Menkes C. J., Laoussadi S., Benveniste J., Arnoux B. Presence of paf-acether in rheumatic diseases. Ann Rheum Dis. 51:1992;29-31.
96. Dulioust A., Hilliquin P., Menkes C. J., Benveniste J., Arnoux B. Paf-acether acetylhydrolase activity is increased in patients with rheumatic diseases. Scand J Rheumatol. 21:1992;161-164.
97. Schlame M., Schmid A. B., Haupt R., Rustow B., Kox W. J. Study of platelet-activating factor acetylhydolase in the perioperative period of patients undergoing cardiac surgery. Shock. 9:1998;313-319.
98. Negro Alvarez J. M., Miralles Lopez J. C., Ortiz Martinez J. L., Abellan Aleman A., Rubio del Barrio R. Platelet-activating factor antagonists. Allergologia Immunopathologia. 25:1997;249-258.
99. Svetlov S. I., Howard K. M., Miwa M., Flickinger B. D., Olson M. S. Interaction of platelet-activating factor with rat hepatocytes: uptake, translocation, metabolism, and effects on PAF-acetylhydrolase secretion and protein tyrosine phosphorylation. Arch Biochim Biophys. 327:1996;113-122.
100. Takata S., Papayianni A., Matsubara M. 15-Hydroxyeicosatetraenoic acid inhibits neutrophil migration across cytokine-activated endothelium. Am J Pathol. 145:1994;541-549.
101. Goudevenos J., Tselepis A. D., Tsoukatos D. Platelet aggregability to platelet activating factor at rest and after exercise in patients with coronary artery disease. Eur Heart J. 16:1995;1036-1043.
102. Lehr H. A., Weyrich A. S., Saetzler R. K. Vitamin C blocks inflammatory platelet-activating factor mimetics created by cigarette smoking. J Clin Invest. 99:1997;2358-2364.
103. Evans D. J., Barnes P. J., Cluzel M., O'Connor B. J. Effects of a potent platelet-activating factor antagonist, SR27417A, on allergen-induced asthmatic responses. Am J Resp Crit Care Med. 156:1997;11-16.
104. Spence D. P., Johnston S. L., Calverley P. M. The effect of the orally active platelet-activating factor antagonist WEB 2086 in the treatment of asthma. Am J Resp Crit Care Med. 149:1994;1142-1148.
105. Tamura G., Takishima T., Mue S. Effect of a potent platelet-activating factor antagonist, WEB-2086, on asthma. A multicenter, double-blind placebo-controlled study in Japan. Adv Exp Med Biol. 416:1996;371-380.
106. Longo W. E., Polities G., Vernava A. M. Platelet-activating factor mediates trinitrobenzene induced colitis. Prostaglandins Leukot Essent Fatty Acids. 51:1994;419-424.
107. Kelly K. J., Tolkoff-Rubin N. E., Rubin R. H. An oral platelet-activating factor antagonist, Ro-24-4736, protects the rat kidney from ischemic injury. Am J Physiol. 271:1996;F1061-F1067.
108. Riera M., Torras J., Herrero I. Neutrophils accentuate renal cold ischemia-reperfusion injury. Dose-dependent protective effect of a platelet-activating factor receptor antagonist. J Pharm Exp Ther. 280:1997;786-794.
109. Kingsnorth A. N., Galloway S. W., Formela L. J. Randomized, double-blind phase II trial of Lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br J Surg. 82:1995;1414-1420.
110. Formela L. J., Wood L. M., Whittaker M., Kingsnorth A. N. Amelioration of experimental acute pancreatitis with a potent platelet-activating factor antagonist. Br J Surg. 81:1994;1783-1785.
111. Herbert J. M., Fraisse L., Bachy A. Biochemical and pharmacological properties of SR 27388, a dual antioxidant and PAF receptor antagonist. J Lipid Med. 8:1993;31-51.
112. Hilliquin P., Guinot P., Chermat-Izard V., Puechal X., Menkes C. J. Treatment of rheumatoid arthritis with platelet activating factor antagonist BN 50730. J Rheumatol. 22:1995;1651-1654.
113. Hilliquin P., Chermat-Izard V., Menkes C. J. A double blind, placebo controlled study of a platelet activating factor antagonist in patients with rheumatoid arthritis. J Rheumatol. 25:1998;1502-1507.
114. Inui K. Participation of platelet activating factor in the pulmonary injury during cardiopulmonary bypass. J Jap Assoc Thor Surg. 41:1993;238-246.
115. Nakae H., Endo S., Inada K. Nitrite/nitrate (NOx) and type II phospholipase A2, leukotriene B4, and platelet-activating factor levels in patients with septic shock. Res Commn Mol Pathol Pharmacol. 92:1996;131-139.
116. Murakami K., Okajima K., Uchiba M. A novel platelet activating factor antagonist, SM-12502, attenuates endotoxin-induced disseminated intravascular coagulation and acute pulmonary vascular injury by inhibiting TNF production in rats. Thromb Haemostasis. 75:1996;965-970.
117. Tenaillon A., Dhainaut J. F., Letulzo U. Y. Efficacy of PAF antagonist BN-52021 in reducing mortality of patients with severe gram negative sepsis. Am Rev Respir Dis. 147:1993;A97.
118. Dhainaut J. F. A., Tenaillon A., Le Tulzo Y. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group. Crit Care Med. 22:1994;1720-1728.
119. Li W., Yuan X. M., Olsson A. G., Brunk U. T. Uptake of oxidized LDL by macrophages results in partial lysosomal enzyme inactivation and relocation. Arteriosclerosis, Thromb Vasc Biol. 18:1998;177-184.
120. Walters-Laporte E., Furman C., Fouquet S. A high concentration of melatonin inhibits in vitro LDL peroxidation but not oxidized LDL toxicity toward cultured endothelial cells. J Cardiovasc Pharmacol. 32:1998;582-592.
121. Chen L., Haught W. H., Yang B. Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine. J Amer Coll Cardiol. 30:1997;569-575.
122. Chan A. C. Vitamin E and atherosclerosis. J Nutr. 128:1998;1593-1596.
123. Jacob R. A. Vitamin C nutriture and risk of atherosclerotic heart disease. Nutr Rev. 56:1998;334-337.
124. Hininger I., Chopra M., Thurnham D. I. Effect of increased fruit and vegetable intake on the susceptibility of lipoprotein to oxidation in smokers. Eur J Clin Nutr. 51:1997;601-606.
125. Reinisch N., Kiechl S., Mayr C. Association of high plasma antioxidant capacity with new lesion formation in carotid atherosclerosis: a prospective study. Eur J Clin Invest. 28:1998;787-792.
126. Sugiyama S., Kugiyama K., Ohgushi M. Supersensitivity of atherosclerotic artery to constrictor effect of cigarette smoke extract. Cardiovasc Res. 38:1998;508-515.
127. Fukumura D., Kurose I., Miura S., Tsuchiya M., Ishii H. Oxidative stress in gastric mucosal injury: role of platelet-activating factor-activated granulocytes. J Gastroenterology. 30:1995;565-571.
128. Napoli C., Triggiani M., Palumbo G. Glycosylation enhances oxygen radical-induced modifications and decreases acetylhydrolase activity of human low density lipoprotein. Basis Res Cardiol. 92:1997;96-105.
129. Sangha O., Stucki G. Vitamin E in therapy of rheumatic diseases. Zeitschrift fur Rheumatologie. 57:1998;207-214.
130. Schwartz J. D., Shamamian P., Schwartz D. S. Cardiopulmonary bypass primes polymorphonuclear leukocytes. J Surg Res. 75:1998;177-182.
131. Lefer A. M., Lefer D. J. Pharmacology of the endothelium in ischemia-reperfusion and circulatory shock. Annu Rev Pharmacol Toxicol. 33:1993;71-90.
132. Tjoelker L. W., Wilder C., Eberhardt C. Anti-inflammatory properties of a platelet-activating factor acetylhydolase. Nature. 374:1995;549-553.
133. Loucks E. B., Symersky P., Qayumi A K. Platelet-activating factor antagonism: a new concept in the management of regional myocardial ischemia-reperfusion injury. J Investigative Surgery. 10:1997;321-338.
134. Butterly D. W., Spurney R. F., Ruiz P. Role of platelet activating factor in kidney transplant rejection in the rat. Kidney International. 48:1995;337-343.
135. Yin M., Buurman W. A., Daemen J. W., Kootstra G. The PAF antagonist TCV-309 reduces graft PMN infiltration and enhances early function of 24-hour-preserved rat kidneys with long warm ischemia. Transplantation. 61:1996;1443-1446.
136. Takada Y., Taniguchi H., Fukunaga K. Prolonged hepatic warm ischemia in non-heart-beating donors: protective effects of FK506 and a platelet activating factor antagonist in porcine liver transplantation. Surgery. 123:1998;692-698.
137. Aikawa N. Cytokine storm in the pathogenesis of multiple organ dysfunction syndrome associated with surgical insults. J Japan Surg Soc. 97:1996;771-777.
138. Fauchier J. P., Babuty D., Fauchier L. Preventive drug therapy of recurrence of atrial fibrillation. Annal Cardiologie Angeiologie. 41:1992;497-507.